Bioverativ Inc. (delisted)

0.00 (0.0%)


Draw Mode:

Volume 0
Bid Price 101.00
Ask Price 104.98
News -
Company Name Stock Ticker Symbol Market Type
Bioverativ Inc. (delisted) BIVV NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 104.98 20:00:00
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 104.98 USD

Bioverativ Inc. (delisted) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 11.33B 107.95M 107.95M $ 1.17B $ 355.57M 3.28 32.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -954.00 0.30%

more financials information »

Bioverativ Inc. News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No BIVV Message Board. Create One! See More Posts on BIVV Message Board See More Message Board Posts

Historical BIVV Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months0.
1 Year0.
3 Years0.
5 Years0.

Bioverativ Inc. Description

Bioverativ Inc is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT009 (part of the True North acquisition) in cold agglutinin disease and other hematology-focused drug candidates. Sanofi's pending acquisition of Bioverativ was announced in January 2018.